Bisphosphonate-enoxacin inhibit osteoclast formation and function by abrogating RANKL-induced JNK signalling pathways during osteoporosis treatment.

J Cell Mol Med · 2021 · PMC8572771 · PMID 34651433

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

failed to reach statistical significanceno p-value reported

showed a trendno p-value reported

Furthermore, the ZOL‐treated groups showed a trend of superior trabecular bone volume compared to that of the low‐dose BE‐treated group, although the differences between the two groups failed to reach statistical significance.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.